Elevation Oncology Future Growth

Future criteria checks 0/6

Elevation Oncology's earnings are forecast to decline at 10.2% per annum while its annual revenue is expected to grow at 78.8% per year. EPS is expected to grow by 3.7% per annum.

Key information

-10.2%

Earnings growth rate

3.7%

EPS growth rate

Biotechs earnings growth	25.1%
Revenue growth rate	78.8%
Future return on equity	n/a
Analyst coverage	Good
Last updated	13 May 2024

Recent future growth updates

Recent updates

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Sep 25

Earnings and Revenue Growth Forecasts

NasdaqGS:ELEV - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-78	-89	-82	6
12/31/2025	N/A	-61	-63	-62	6
12/31/2024	N/A	-48	-42	-44	6
3/31/2024	N/A	-39	-49	-49	N/A
12/31/2023	N/A	-46	-56	-56	N/A
9/30/2023	N/A	-57	-62	-62	N/A
6/30/2023	N/A	-85	-93	-93	N/A
3/31/2023	N/A	-95	-88	-88	N/A
12/31/2022	N/A	-95	-86	-85	N/A
9/30/2022	N/A	-86	-77	-77	N/A
6/30/2022	N/A	-59	-40	-40	N/A
3/31/2022	N/A	-44	-35	-35	N/A
12/31/2021	N/A	-32	-30	-30	N/A
9/30/2021	N/A	-31	-25	-25	N/A
6/30/2021	N/A	-22	-22	-21	N/A
3/31/2021	N/A	-20	-20	-20	N/A
12/31/2020	N/A	-17	-12	-12	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ELEV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ELEV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ELEV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ELEV is forecast to have no revenue next year.

High Growth Revenue: ELEV is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ELEV's Return on Equity is forecast to be high in 3 years time

Elevation Oncology Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 24% to US$6.00

Price target decreased by 19% to US$4.17

Price target decreased to US$5.17

Recent updates

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Elevation Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Elevation Oncology, Inc., Annual General Meeting, Jun 13, 2024

Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors

Elevation Oncology: Rising On News, But Not The Time To Buy

Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021

New minor risk - Share price stability

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021

Elevation Oncology, Inc Appoints Joseph J. Ferra, Jr. as Chief Executive Officer

New major risk - Financial position

New major risk - Shareholder dilution

Elevation Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $50.062056 million.

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Price target increased by 24% to US$6.00

Advisor notifies of intention to sell stock

Advisor notifies of intention to sell stock

Price target decreased by 19% to US$4.17

Elevation Oncology, Inc. Announces Management Changes

Price target decreased to US$5.17

Elevation Oncology GAAP EPS of -$0.86 misses by $0.07

Elevation Oncology secured $50M loan facility with K2 HealthVentures

Now 36% undervalued after recent price drop

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely

Elevation Oncology, Inc. Appoints David Dornan as Chief Scientific Officer

Elevation Oncology, Inc., Annual General Meeting, Jun 17, 2022

Elevation Oncology, Inc. Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022

Less than half of directors are independent

We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Elevation Oncology, Inc. has completed an IPO in the amount of $100 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies